VPRIV

Infusion Diary for VPRIV 400 Units powder for solution for infusion for Home Infusion

General Information

Patient
Name:
Address:
City:
Telephone:
Email:
Caregiver (if applicable)
Name:
Address:
City:
Telephone:
Email:
Treating Physician
Name:
Address:
City:
Telephone:
Email:
Nurse
Name:
Address:
City:
Telephone:
Email:
Pharmacy
Name:
Address:
City:
Telephone:
Email:
National Emergency Number
Telephone:

Administration Details

VPRIV® administered since (DD/MM/YYYY):
First VPRIV® infusion at home (DD/MM/YYYY):
VPRIV® dose, frequency:
VPRIV® infusion rate:
Indicate support to be provided by nurse:

Emergency Plan (To be completed by the treating physician)

Necessary actions in the event of a serious infusion reaction:

1. Stop the infusion		☐
2. Call the national emergency number:		☐
3. Call the treating physician:		☐

This resource was developed by Shire as part of a commitment made in the Risk Minimisation Measures for VPRIV®. Please report any suspected adverse event(s) to the MHRA Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard and to Shire at drugsafety@shire.com

EXA/UK//0261 Date of preparation: February 2019

Shire

© Shire 2019

VPRIV

Infusion Log (to be completed at each infusion)

Infusion number:
Date of infusion:
Name of person giving the infusion (patient, caregiver or homecare nurse):
Patient's general health:
Patient's weight (kg):
Dose and rate of infusion:
Lot number:
Numbers of vials used:
Expiry date:
Time infusion started:
Time infusion stopped:
General remarks:
Any problems related to infusion?
• Any action taken:

Infusion number:
Date of infusion:
Name of person giving the infusion (patient, caregiver or homecare nurse):
Patient's general health:
Patient's weight (kg):
Dose and rate of infusion:
Lot number:
Numbers of vials used:
Expiry date:
Time infusion started:
Time infusion stopped:
General remarks:
Any problems related to infusion?
• Any action taken:

This resource was developed by Shire as part of a commitment made in the Risk Minimisation Measures for VPRIV®. Please report any suspected adverse event(s) to the MHRA Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard and to Shire at drugsafety@shire.com

EXA/UK//0261 Date of preparation: February 2019

Shire

© Shire 2019